Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

83.77 +2.62 (+3.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,939,777
Open 84.31
Bid (Size) 83.55 (100)
Ask (Size) 83.64 (200)
Prev. Close 81.15
Today's Range 83.37 - 85.02
52wk Range 61.24 - 86.57
Shares Outstanding N/A
Dividend Yield 1.23%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why AstraZeneca Stock Topped the Market on Thursday
Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter. 
Via The Motley Fool
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026. 
Via Benzinga
Topics Government

Performance

YTD
+27.2%
+27.2%
1 Month
-2.0%
-2.0%
3 Month
+13.8%
+13.8%
6 Month
+19.6%
+19.6%
1 Year
+26.4%
+26.4%

More News

Read More
AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable
Via Benzinga
AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar
Via Investor's Business Daily
Earnings Scheduled For November 6, 2025
Via Benzinga
Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs
Via Stocktwits
AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer
Via Stocktwits
AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday?
Via Benzinga
Topics Artificial Intelligence
AstraZeneca's 9M and Q3 2025 Financial Results
From AstraZeneca
Via Business Wire
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
Via TokenRing AI
Topics Artificial Intelligence
Snowflake And SAP Bridge Enterprise Data Silos In Major AI Integration Push
Via Benzinga
Topics Artificial Intelligence
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
Via Investor's Business Daily
Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations
Via MarketMinute
Topics Government World Trade
3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years
Via MarketBeat
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership
Via Benzinga
Topics Initial Public Offering
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
Via MarketMinute
Danaher Corporation Poised for Growth as Q3 2025 Earnings Spark Optimism
Via MarketMinute
Peering Into AstraZeneca PLC's Recent Short Interest
Via Benzinga
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
From AstraZeneca
Via Business Wire

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 83.77
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 11/06/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.